Dow Division of Health Services Research, Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA.
Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
BJU Int. 2019 Jul;124(1):55-61. doi: 10.1111/bju.14551. Epub 2018 Nov 12.
To characterise bone scan use, and potential overuse, after radical prostatectomy (RP) using data from a large, national integrated delivery system. Overuse of imaging is well documented in the setting of newly diagnosed prostate cancer, but whether overuse persists after RP remains unknown.
We identified 12 269 patients with prostate cancer treated with RP between 2005 and 2008 using the Veterans Administration Central Cancer Registry. We used administrative and laboratory data to examine rates of bone scan use, including preceding prostate-specific antigen (PSA) levels, and receipt of adjuvant or salvage therapy. We then performed multivariable logistic regression to identify factors associated with post-RP bone scan use.
At a median follow-up of 6.8 years, one in five men (22%) underwent a post-RP bone scan at a median PSA level of 0.2 ng/mL. Half of bone scans (48%) were obtained in men who did not receive further treatment with androgen-deprivation or radiation therapy. After adjustment, post-RP bone scan was associated with a prior bone scan (adjusted odds ratio [aOR] 1.55, 95% confidence interval [CI] 1.32-1.84), positive surgical margin (aOR 1.68, 95% CI 1.40-2.01), preoperative PSA level (aOR 1.02, 95% CI 1.01-1.03), as well as Hispanic ethnicity, Black race, and increasing D'Amico risk category, but not with age or comorbidity.
We found a substantial rate of bone scan utilisation after RP. The majority were performed for PSA levels of <1 ng/mL where the likelihood of a positive test is low. More judicious use of imaging appears warranted in the post-RP setting.
利用大型国家综合交付系统的数据,描述根治性前列腺切除术(RP)后骨扫描的使用情况及其潜在的过度使用情况。在新诊断的前列腺癌治疗中,影像学过度使用的情况已有充分记录,但 RP 后是否仍存在过度使用情况尚不清楚。
我们利用退伍军人事务部中央癌症登记处的数据,确定了 2005 年至 2008 年间接受 RP 治疗的 12269 例前列腺癌患者。我们使用行政和实验室数据检查了骨扫描的使用率,包括之前的前列腺特异性抗原(PSA)水平以及接受辅助或挽救性治疗的情况。然后,我们进行多变量逻辑回归分析,以确定与 RP 后骨扫描使用相关的因素。
在中位随访 6.8 年期间,五分之一(22%)的男性在 PSA 水平中位数为 0.2ng/mL 时接受了 RP 后骨扫描。一半(48%)的骨扫描是在未接受雄激素剥夺或放射治疗的男性中进行的。调整后,RP 后骨扫描与之前的骨扫描(校正优势比 [aOR]1.55,95%置信区间 [CI]1.32-1.84)、阳性手术切缘(aOR1.68,95%CI1.40-2.01)、术前 PSA 水平(aOR1.02,95%CI1.01-1.03)以及西班牙裔、黑人种族和 D'Amico 风险类别增加有关,但与年龄或合并症无关。
我们发现 RP 后骨扫描的使用率很高。其中大多数是在 PSA 水平<1ng/mL 时进行的,此时阳性检测的可能性较低。在 RP 后,更需要谨慎使用影像学检查。